CN113041505A - Using method of lamp group for treating myopia - Google Patents
Using method of lamp group for treating myopia Download PDFInfo
- Publication number
- CN113041505A CN113041505A CN202110283267.6A CN202110283267A CN113041505A CN 113041505 A CN113041505 A CN 113041505A CN 202110283267 A CN202110283267 A CN 202110283267A CN 113041505 A CN113041505 A CN 113041505A
- Authority
- CN
- China
- Prior art keywords
- lamp
- desk lamp
- flashlight
- light
- desk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001491 myopia Diseases 0.000 title claims abstract description 40
- 230000004379 myopia Effects 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 29
- 238000001228 spectrum Methods 0.000 claims abstract description 22
- 230000008439 repair process Effects 0.000 claims abstract description 7
- 238000005286 illumination Methods 0.000 claims description 13
- 230000007613 environmental effect Effects 0.000 claims description 11
- 238000009434 installation Methods 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims description 2
- 230000001678 irradiating effect Effects 0.000 claims description 2
- 239000000843 powder Substances 0.000 abstract description 24
- 230000004438 eyesight Effects 0.000 abstract description 12
- 230000002265 prevention Effects 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 9
- 238000011161 development Methods 0.000 abstract description 8
- 230000004436 pseudomyopia Effects 0.000 abstract description 6
- 230000036961 partial effect Effects 0.000 abstract description 3
- 230000002441 reversible effect Effects 0.000 abstract description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 12
- 230000006872 improvement Effects 0.000 description 12
- 239000011651 chromium Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 10
- 238000003466 welding Methods 0.000 description 9
- 238000000295 emission spectrum Methods 0.000 description 8
- 208000017520 skin disease Diseases 0.000 description 8
- 238000010586 diagram Methods 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 229910052761 rare earth metal Inorganic materials 0.000 description 7
- 238000005067 remediation Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 6
- -1 nitrogen (oxygen) oxide phosphor Chemical compound 0.000 description 6
- 210000001525 retina Anatomy 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 210000003161 choroid Anatomy 0.000 description 5
- 229960003638 dopamine Drugs 0.000 description 5
- 238000005498 polishing Methods 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 208000000453 Skin Neoplasms Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 238000002428 photodynamic therapy Methods 0.000 description 4
- 230000004515 progressive myopia Effects 0.000 description 4
- 238000005096 rolling process Methods 0.000 description 4
- 210000003786 sclera Anatomy 0.000 description 4
- 238000005507 spraying Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010020675 Hypermetropia Diseases 0.000 description 3
- 229910020491 K2TiF6 Inorganic materials 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- 230000004323 axial length Effects 0.000 description 3
- 229910052788 barium Inorganic materials 0.000 description 3
- 238000005452 bending Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000005242 forging Methods 0.000 description 3
- 238000005246 galvanizing Methods 0.000 description 3
- 230000004305 hyperopia Effects 0.000 description 3
- 201000006318 hyperopia Diseases 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000000258 photobiological effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010079 rubber tapping Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010009244 Claustrophobia Diseases 0.000 description 2
- 208000010412 Glaucoma Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000022873 Ocular disease Diseases 0.000 description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 2
- 238000000862 absorption spectrum Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000004645 aluminates Chemical class 0.000 description 2
- 230000004329 axial myopia Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000004512 die casting Methods 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000004423 myopia development Effects 0.000 description 2
- 208000019899 phobic disease Diseases 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 150000002910 rare earth metals Chemical class 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009978 visual deterioration Effects 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 229910016064 BaSi2 Inorganic materials 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910017623 MgSi2 Inorganic materials 0.000 description 1
- 208000035965 Postoperative Complications Diseases 0.000 description 1
- 229910004122 SrSi Inorganic materials 0.000 description 1
- 239000005084 Strontium aluminate Substances 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- AYJRCSIUFZENHW-DEQYMQKBSA-L barium(2+);oxomethanediolate Chemical compound [Ba+2].[O-][14C]([O-])=O AYJRCSIUFZENHW-DEQYMQKBSA-L 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000007590 electrostatic spraying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229910001940 europium oxide Inorganic materials 0.000 description 1
- AEBZCFFCDTZXHP-UHFFFAOYSA-N europium(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Eu+3].[Eu+3] AEBZCFFCDTZXHP-UHFFFAOYSA-N 0.000 description 1
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 1
- 229910001938 gadolinium oxide Inorganic materials 0.000 description 1
- 229940075613 gadolinium oxide Drugs 0.000 description 1
- CMIHHWBVHJVIGI-UHFFFAOYSA-N gadolinium(iii) oxide Chemical compound [O-2].[O-2].[O-2].[Gd+3].[Gd+3] CMIHHWBVHJVIGI-UHFFFAOYSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000005337 ground glass Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052909 inorganic silicate Inorganic materials 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 235000019837 monoammonium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- IBIRZFNPWYRWOG-UHFFFAOYSA-N phosphane;phosphoric acid Chemical compound P.OP(O)(O)=O IBIRZFNPWYRWOG-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 238000004381 surface treatment Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
Abstract
The invention provides a using method of a lamp group for treating myopia, which belongs to the technical field of vision treatment and comprises the following steps of using a desktop desk lamp, a flashlight, a ceiling lamp and a wall lamp: s1, environment light repairing; s2, emergency repair; s3, common eye treatment; s4, high intensity ocular treatment; the four types of lamps packaged by traditional LED chips are replaced by the fluorescent powder material with the red light-far red light excited by the blue light and the full-spectrum partial spectrum structure, and the prevention and control effects on the far vision reserve stage, the teenager (pseudomyopia) accelerated development stage, the near vision reversible development stage and the axial near vision stage of the infant can be achieved respectively.
Description
Technical Field
The invention relates to the technical field of vision treatment, in particular to a using method of a lamp set for treating myopia.
Background
Myopia is a very serious health problem in our country, especially in young and young years. There is still a lack of new effective myopia prevention and control solutions.
In the existing scheme for improving myopia, surgical strategies (laser surgery, including half minute second, full femtosecond, Trans-PRK surgery and the like, mainly aiming at laser treatment of cornea; the other type is ICL crystal implantation and the like) have corresponding limitations on the age, myopia progression degree, refractive examination result, basic disease conditions and the like of a patient, and postoperative complications, relapse and the like are frequent, so that the surgical strategies are not suitable for children with low age, early myopia and prevention and control of main requirements; non-operative strategies such as a corneal plastic lens are expensive and easy to relapse, the individual difference of drug therapy such as low-concentration atropine is large, the long-term curative effect is unstable and more concurrent risks are easy to generate, the equivalent lattices of various eye protection instruments, glasses and acupuncture point massage instruments are expensive, the using method is complex, the popularization is difficult, and the effect is not accepted by the academia; the measures of myopia prevention and control schemes based on etiology, such as eye exercises, outdoor exercises, reduction of operation and mobile phone use time, food therapy and the like, are not verified by large-scale clinical RCT tests and epidemiological tests at present, and the effect of the myopia prevention and control schemes is still in the principle stage. In recent years, photobiological modulation (PBM) strategies based on optical component science disclose the prevention and control effects of full spectrum white light and 680-850nm far infrared light on myopia.
Recent research shows that the dopamine secretion enhancement sensitive spectrum of the retina of the eye is red light with a wave band of over 624nn and an illuminance of over 400 LUX. The far-red light of 650nm is used for enabling retinal epithelial pigment cells to secrete dopamine, so that the increase of the axis of the eye is effectively inhibited, the children without myopia are prevented in advance, and the degree of the children with myopia is not increased any more. In addition, 650nn of red light is warm-warming, and directly irradiates the retina, the choroid behind the retina is also affected, thereby restoring the thinned choroid to normal thickness, providing sufficient oxygen to the choroid, improving blood circulation in the fundus, and allowing no further increase in myopia. Summary of photobioregulation effects: acting on the retina: can stimulate dopamine production, thereby inhibiting the increase of the axis of the eye; acting on the choroid: can improve the microcirculation of the eyeground, recover the thickness of the choroid and delay the growth of the axis of the eye; acting on the sclera: can improve the anoxic condition of sclera, thereby controlling the myopia development.
In the traditional white light LED which is made of white light by matching the blue light technology and fluorescent powder, a very strong peak exists in a blue light wave band in a spectrum component, and excessive radiation can cause harm to human eyes in a short time or in a short moment. Light Emitting Diodes (LEDs) based on iii-V and ii-vi inorganic semiconductor materials, which belong to point light sources, are widely used for instrument display and illumination for life, and LED surface light sources represented by organic electroluminescent diodes (OLEDs) and quantum dot light emitting diodes (QLEDs) are widely used as mobile phone and television display screens, but their blue light hazards and their influence on the scholar rhythm are more and more emphasized by people along with the popularization and low-age of smart phones: the vision is sharply reduced due to the long-time use of the mobile phone. Probably due to the fact that the existing mobile phone light source LED lacks far-red light, insufficient secretion of dopamine in eyes causes oxygen deficiency of sclera, incapability of repairing and regenerating retinal cells and increase of eye axis. Especially, when the mobile phone is watched at night without sunlight, the mobile phone is more harmful to the vision. The LED lighting source has the same problems as a mobile phone, but the popularization rate of the LED lighting source is far less than that of the LED lighting source in a display backlight source, and the day and night high-frequency comprehensive light source contact mode of the 'various display screen backlight sources' + 'table lamps' + 'top lamps' has great influence on the eyesight of modern people, particularly immature eyes.
In summary, the usage patterns of the conventional light source and the lamps with different light sources have great influence on the generation and deterioration of myopia. The largest mass production scale of the current LED chips is that the blue light chips with the wavelength peak value of 450-460nm can generate blue light harm to human eyes and even promote the occurrence and development of myopia.
Disclosure of Invention
Aiming at the technical defects, the invention aims to provide a using method of a lamp set for treating myopia, which utilizes a fluorescent powder material with red light-far red light excited by blue light and a full-spectrum partial spectrum structure to replace the traditional LED chip packaged four types of lamps; through the combination scheme of the four types of lamp combination and the combination scheme of the use time and the intensity, four novel schemes for preventing and controlling myopia based on the four types of combined lamps and the principle of photo biological regulation (PBM) are provided: the environment restoration mode (E), the emergency restoration mode (S), the common eye using mode (G) and the high-strength eye using mode (H) can respectively achieve the prevention and control effects on the hyperopia reserve stage, the juvenile (pseudomyopia) accelerated development stage, the myopia reversible development stage and the axial myopia stage of the infant.
In order to solve the technical problems, the invention adopts the following technical scheme:
a method of using a lamp set for treating myopia, using a desk lamp, flashlight, overhead light and wall lamp, the method comprising:
s1 environmental light repair
The lamp combination mode is as follows: a wall lamp is added to the ceiling lamp; or a ceiling light; or a wall lamp;
the use method comprises the following steps: through space planning, the light emitting direction of the suspended ceiling lamp is upward and downward irradiation, and the vertical distance from the mounting position to the top surface is 0.5-1.5 m; the light emitting direction of the wall lamp is backward and forward irradiation, and the vertical distance between the installation position and the ground is 0-2.5 m; the full spectrum or far-red spectrum is adjusted in intensity, so that the light intensity of a local environment is more than or equal to 4000lx, and the maintaining time is more than or equal to 6h or 12 h;
s2, emergency repair
The lamp combination mode is as follows: a flashlight; or a flashlight with a desk lamp;
the use method comprises the following steps: turning the flashlight or the desk lamp to a strong treatment mode, intermittently and continuously irradiating the eye in a non-direct contact manner, wherein the shortest distance is 0.5-3cm, and ten minutes is one round for three times every day, so that the accumulated light intensity of one round is more than or equal to 15000lx, and the maintaining time is more than or equal to 3 rounds per week;
s3 common eye treatment
The lamp combination mode is as follows: a desk lamp; or a desk lamp and a wall lamp; or a desk lamp and a ceiling lamp are added; or a desk lamp, a wall lamp and a ceiling lamp;
the use method comprises the following steps: the desk lamp is adjusted to a working mode, or background illumination is added in an auxiliary mode, namely a wall lamp and a ceiling lamp, the total environment intensity is larger than or equal to 800lx, the distance between the desk lamp and the eyes is larger than 0.1m, the single use time is smaller than or equal to 4h, or the total treatment time is smaller than or equal to 6h when the desk lamp is used intermittently;
s4 high-intensity eye treatment
A lamp combination mode; the desk lamp is provided with a flashlight; or a desk lamp and a flashlight and a wall lamp; or a desk lamp, a flashlight and a ceiling lamp; or a desk lamp, a flashlight, a wall lamp and a ceiling lamp;
the use method comprises the following steps: the desk lamp is adjusted to a working mode, or background illumination is added in an auxiliary mode, namely a wall lamp and a ceiling lamp, the total environment intensity is larger than or equal to 800lx, the distance between the desk lamp and the eyes is larger than 0.1m, the desk lamp is used for treatment every 2 hours in the environment, the non-direct contact type irradiation lasts for more than or equal to three minutes, and the shortest distance between the desk lamp and the eyes is 0.5-3 cm.
The invention has the beneficial effects that: the fluorescent powder material with the red light-far red light excited by blue light and the full-spectrum partial spectrum structure is used for replacing the traditional LED chip packaged four types of lamps; through the combination scheme of the four types of lamp combination and the combination scheme of the use time and the intensity, four novel schemes for preventing and controlling myopia based on the four types of combined lamps and the principle of photo biological regulation (PBM) are provided: the environment restoration mode (E), the emergency restoration mode (S), the common eye using mode (G) and the high-strength eye using mode (H) can respectively achieve the prevention and control effects on the hyperopia reserve stage, the juvenile (pseudomyopia) accelerated development stage, the myopia reversible development stage and the axial myopia stage of the infant.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings used in the description of the embodiments or the prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present invention, and for those skilled in the art, other drawings can be obtained according to the drawings without creative efforts.
Fig. 1 is a schematic structural diagram of a desk lamp using a lamp set for treating myopia according to an embodiment of the present invention;
FIG. 2 is a schematic diagram of a flashlight of a method for using a lamp set for treating myopia according to an embodiment of the present invention;
FIG. 3 is a schematic diagram of a suspended ceiling lamp for use in a method of using a lamp set for treating myopia according to an embodiment of the present invention;
fig. 4 is a schematic structural diagram of a wall lamp of a method for using a lamp group for treating myopia according to an embodiment of the present invention;
FIG. 5 is a diagram of the emission spectrum of a far-red LED packaged by a method for using a lamp set for treating myopia according to an embodiment of the present invention;
FIG. 6 is a graph of emission spectra of a blue LED chip and a green LED chip according to an embodiment of the present invention;
FIG. 7 is a graph showing emission spectra of a blue LED combined with a far-red LED and a green LED combined with a far-red LED in accordance with an embodiment of the present invention;
FIG. 8 is a diagram showing a retina slice of a mouse of a control group (a) irradiated by a blue LED and a green LED, and a diagram showing a retina slice of an experimental group (b) irradiated by a blue LED combined with a far-red LED and a green LED combined with a far-red LED, in an animal experimental basis according to an embodiment of the present invention;
FIG. 9 shows the use of YAl in an embodiment of the present invention3B4O12:Cr3 +A comparison graph of the emission spectrum of the packaged far-red LED and the absorption spectrum of the HeLa cell irradiated by the 830nm far-red light;
FIG. 10 illustrates the use of YAl in an embodiment of the present invention3B4O12:Cr3 +And Mg4Nb2O9:Cr3 +A comparison graph of the emission spectrum of the packaged far-red LED and the absorption spectrum of the HeLa cell irradiated by the 830nm far-red light;
fig. 11 shows an embodiment of the present invention in which a blue LED chip is used in combination with β -SIALON: eu (Eu)2 +Green phosphor and K2TiF6:Mn4 +A white light LED emission spectrum packaged by red fluorescent powder;
fig. 12 shows an embodiment of the present invention in which a blue LED chip is used in combination with β -SIALON: eu (Eu)2 +Green phosphor, K2TiF6：Mn4 +Red phosphor and YAl3B4O12：Cr3 +The light emission spectrum of the LED packaged by the far-red light material;
FIG. 13 shows YAl as far-red light material3B4O12:Cr3 +And Mg4Nb2O9：Cr3 +Matching a blue light LED chip and a beta-SIALON: eu (Eu)2 +Green phosphor and K2TiF6：Mn4+An LED emission spectrum packaged by red phosphor;
FIG. 14 is a comparison of the improvement in myopia progression for a long-term follow-up visit to a cohort of children aged 3-8 years (A) using the "environmental remediation protocol (E)";
FIG. 15 is a comparison of the improvement in myopia progression for a long-term follow-up visit to a 9-15 year old (B) cohort of children using the "environmental remediation protocol (E)";
FIG. 16 is a comparison of the improvement in myopia progression for long-term follow-up of a cohort of children >15 years (C) using an "environmental remediation protocol (E)";
FIG. 17 is a comparison of the improvement in ocular axial length (mm) for a long-term follow-up visit to a cohort of children aged 3-8 years (A) using the "environmental remediation protocol (E)";
FIG. 18 is a comparison of the improvement in ocular axial length (mm) for a long-term follow-up visit to a cohort of children 9-15 years (B) using the "environmental remediation protocol (E)";
FIG. 19 is a comparison of the improvement in ocular axial length (mm) for a long-term follow-up visit to a cohort of children aged 15 (C) using the "environmental remediation protocol (E)";
FIG. 20 is a comparison of the short-term improvement in vision after general eye use behavior for full spectrum white/far-red light with a conventional common table lamp light source using a "common eye use treatment protocol (G)";
FIG. 21 is a comparison of short term improvement in vision after application of the "Emergency repair protocol (S)" for high intensity eye use behavior (harmful light sources);
FIG. 22 is a short-term self-control vision improvement result for a "general eye treatment regimen (G)" should be used after the use of a general light fixture;
FIG. 23 is a short-term self-control vision improvement result using a "high intensity eye treatment protocol (H)" followed by a normal light fixture;
FIG. 24 is a short-term self-control vision improvement result using a "common eye treatment protocol (G)" after cross-use of a common light fixture;
fig. 25 is a short-term self-control vision improvement result using the "high intensity eye treatment protocol (H)" after cross-use of a common light fixture.
Description of reference numerals:
the LED lamp comprises a lamp bead 1, a lamp holder 2, a lamp post 3, a chassis 4, a controller 5, a lamp body 6, a socket 7, a control key 8, a silica gel pad seat 9, a lampshade 10 and an L-shaped support rod 11.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
A method for using a lamp group for treating myopia comprises using a desktop desk lamp, a flashlight, a ceiling lamp and a wall lamp; the desktop desk lamp, the flashlight, the ceiling lamp and the wall lamp are all provided with lamp beads; the lamp bead is prepared from the following raw materials: transparent silica gel, far-red fluorescent powder and colored fluorescent powder; the weight ratio is as follows: transparent silica gel: far-red fluorescent powder: the ratio of the colored fluorescent powder to the fluorescent powder is 100:100: 1-10: 10: 1.
The myopia scheme is a novel myopia prevention and control scheme based on four therapeutic lamps (desktop table lamps, flashlights, overhead lamps and wall lamps) for exciting full spectrum and far red light (650nm) fluorescent powder and a light biological regulation (PBM) principle, specifically is four schemes of ' environment restoration mode (E) ' emergency restoration mode (S) ' common eye using mode (G) ' high-intensity eye using mode (H) ', and specifically comprises the following steps:
1. packaging the light-emitting chip:
1.1 adopt the technical route of a fluorescence conversion type LED device (different from a multi-chip packaging technical scheme). The fluorescent material with far-red light (and/or) having a sunlight visible light part spectrum structure is adopted to convert blue light emitted by the LED chip into far-red light (and/or) white light, and a light emitting chip or a lamp bead is prepared and further integrated into an illumination light source.
1.2 the fluorescent powder with the spectrum structure of the sunlight visible light part comprises:
cyan phosphor: the emission wavelength is 480-520nm, and the peak value of emission wavelength can be 512nm (Ba)0.8Sr0.2)2SiO4: eu or ② emitting Ba with wavelength peak value of 505nm2SiO4: eu or ③ 500nm Sr4Al14O25：Eu；
Green phosphor powder: selecting beta-SIALON with peak emission wavelength of 557 nm: eu or ② beta-SIALON with peak emission wavelength of 540 nm: eu or ③ SrSi with 545nm emission wavelength peak value2O2N2：Eu；
Red fluorescent powder: selecting CaAlSiN with peak value emission wavelength of 620-660nm3: eu or ② Sr2Si5N8: eu; orange fluorescent powder: selecting (Sr) with peak emission wavelength of 600nm0.8Ba0.2)3SiO5：Eu；
Blue fluorescent powder: ca8-xLa2(PO4)5O2：xEu2 +(ii) a x is 0.001-0.10, and is mainly divided into several major systems: sulfide phosphor, aluminate phosphor, silicate phosphor, phosphate phosphor, and silicon-based nitrogen (oxygen) oxide phosphor: sulfide blue phosphors such as CaLaGa3S60：Eu2 +(ii) a Aluminate blue phosphors such as BaMgAl10O17：Eu2 +(ii) a Silicate blue phosphors such as: MSi04：Eu2 +(M＝Ca、Sr、Ba)、Y2Si05：Ce3 +、SrAl2Si2O8：Eu2 +、M3MgSi208：Eu2 +(M ═ Ba, Sr), etc.; phosphate phosphors such as LiSrPO4：Eu2 +、KSrPO4：Eu2 +And SrMg2(PO4)2：Eu2 +And the like. Silicon-based nitrogen (oxide) blue phosphor such as BaSi202N2：Eu2 +、Ca2Si5N8：Ce3 +And Ba2Si5N8：Ce3 +Etc.; single-matrix white light emitting fluorophosphate fluorescent powder for white light LED: ba3GdNa(PO4)3F：xEu2 +Wherein x is 0.001-0.10, and the raw materials according to the chemical formula are barium carbonate, ammonium dihydrogen phosphate, gadolinium oxide, sodium fluoride and europium oxide.
1.3 the far-red phosphor comprises: cr (chromium) component3 +Activated mixture of rare earth borate and rare earth boroaluminate. Chemical formula of rare earth borate is RBO3：Cr3 +Wherein R is a rare earth element; wherein Cr is3 +The activated rare earth borate accounts for 0-10% of the far-red fluorescent powder by mass; in the rare earth borate, Cr3 +The molar concentration of A1 atoms is 1-8%, preferably 4%. ② the chemical formula of the rare earth boroaluminate is R (Al, X)3(B03)4：Cr3 +(ii) a Wherein X is in RAI3(B03)4Elements which can replace Al atoms in the lattice and can keep the crystal structure of the lattice unchanged, and preferably single or mixed components of Ga, Sc, Mg, Ti and Zr; the red fluorescent powder comprises: (Ca, Sr) AlSiN3：Eu2 +Or M2Si5N8：Eu2 +(M ═ Sr, Ca, Ba, Mg). Fully mixing the far-red fluorescent powder and the red fluorescent powder in a predetermined ratio in transparent silica gel, wherein the mass ratio of the far-red fluorescent powder to the red fluorescent powder is 199: 1-1: 1.
2. assembling four types of lamps:
2.1 first type: desktop treatment type desk lamp (A)
The method mainly comprises the following steps: lamp pearl 1, lamp holder 2, lamp body 6, chassis 4, control button 5, as figure 1:
1. the lamp post production process comprises the following steps:
1) blank rod: plate rolling machine flattening → rolling shear cutting → large bending machine pipe rolling → automatic submerged arc welding → mechanical rounding and straightening;
2) flange: plate shearing → plasma equipment cuts the flange hole;
3) and (3) mounting a flange: inserting the lamp post into the flange hole → welding the lamp post and the flange inside and outside → welding the reinforcing rib;
4) galvanizing: adopting inner and outer hot galvanizing, wherein the thickness of a zinc layer is more than or equal to 80 microns;
5) spraying plastics: galvanized lever grinding → spraying → heating → cooling → packaging.
2. The process flow of the lamp post is as follows:
plate (straightening unit) → cutting (plasma cutting machine) → bending (large bending machine set) + tightening up weld seam (automatic submerged arc welding machine) → straightening and polishing (straightening unit) → hot galvanizing, plastic spraying (powder electrostatic spraying)
3. The lamp production process comprises the following steps:
1) lamp holder: welding the LED lamp holder made of the luminescent material on a circuit board;
2) a lamp body: die-casting and molding by a die-casting machine;
3) polishing: polishing by adopting an advanced process;
4) tapping: tapping by a tapping machine;
5) spraying: forming in a production line;
6) assembling and checking the surface paint baking effect and checking the sealing property.
2.2 second class: hand-held blaze mobile therapeutic type torch (B)
The method mainly comprises the following steps: lamp pearl 1, lamp holder 2, lamp body 3, socket 7, control button 8, detachable eye silica gel base 9, as figure 2:
1. the mold for manufacturing the strong light flashlight comprises a female mold and a male mold. An opening and a detachable eye compress base corresponding to the LED lamp holder are arranged at the front end of the highlight flashlight shell, and inserting parts corresponding to each other are arranged at the rear end of the highlight flashlight shell;
2. forging the highlight flashlight shell by using a die;
3. roughly polishing the surface of the shell of the hard light flashlight by using a numerical control lathe;
4. carrying out mirror surface treatment on the surface of the flashlight shell;
5. hardening and insulating the surface of the shell of the flashlight;
6. welding an LED lamp cap made of the luminescent material on a flashlight circuit board, electrically connecting the LED lamp cap with the flashlight circuit board, and welding the flashlight circuit board in the strong light flashlight shell;
7. welding a high-capacity lithium battery in a high-capacity mobile power supply shell;
8. carrying out charge and discharge protection test on the high-capacity lithium battery;
9. and the highlight flashlight shell and the high-capacity mobile power supply shell are well inserted, and the high-capacity lithium battery is electrically connected with the flashlight circuit board.
2.3 third class: ceiling lamp (C) simulating natural light (full spectrum)/far-red light component
The method mainly comprises the following steps: lamp pearl 1, lamp holder 2, lamp shade 10, chassis 4, as figure 3:
the structure includes the lamp body (bell-shaped frame of copper, LED bulb) of below, the lamp shade of top, built-in integrated circuit bus, control chip, brightness control device and go-between part:
the manufacturing process comprises the following steps:
1. a plurality of luminous lamp beads with the front and back surfaces provided with the LED chips based on the fluorescent materials are arranged in the frame, and a ground glass lampshade is connected below the frame in a buckling mode;
2. the frame is connected with a lampshade with a hole above through a connecting rod;
3. and (4) installing the automatic timing switch into a circuit and packaging.
2.4 fourth type: day/night treatment wall lamp (D)
The method mainly comprises the following steps: lamp pearl 1, lamp holder 2, lamp shade 10, chassis 4, L type bracing piece 11, as figure 4:
the wall lamp structure: the LED lamp comprises a lamp holder, an L-shaped supporting rod, a lamp body (comprising a bulb and a lampshade), a built-in integrated circuit bus, a control chip, a brightness adjusting device and a connecting ring part.
The manufacturing process comprises the following steps:
1. manufacturing a lamp holder and a lamp shade: molding → feeding, namely forging and pressing the lamp holder and the lamp shade → milling holes on the lamp holder, and nailing the lamp holder into a wall surface → removing burrs;
2. manufacturing an L-shaped support rod: forging and pressing a stainless steel sheet → rolling into a stainless steel hollow rod → welding into an L-shaped rod → grinding and polishing;
3. manufacturing a connecting ring part;
4. the system is sequentially connected with a built-in integrated circuit bus, a control chip, a comparator, a brightness adjusting device and a bulb;
5. the therapeutic lamp bulb based on the fluorescent material and other devices are arranged in the lampshade, and the lamp holder, the L-shaped support rod and the lamp body are connected by the connecting ring parts.
3. Combined prevention and control scheme for treating myopia
3.1 "environmental remediation protocol (E)"
The lamp combination mode is as follows: ceiling lamp (C) + wall lamp (D) or ceiling lamp (C) or wall lamp (D)
Explanation: the closed or semi-closed environment such as houses, classrooms and the like is maintained under high-level full-spectrum white light (and/or) far-red light through an environment light source, the basic illumination value is improved, and myopia is prevented from occurring or progressing, and experiments show that the speed of myopia degree development (1.7-10 times) and the increase speed of an eye axis (1.2-24.9 times) can be delayed.
The use method comprises the following steps: through space planning, the light emitting direction of the ceiling lamp (C) is upward (top surface) and downward (bottom surface) irradiation, and the vertical distance from the installation position to the top surface is 0.5-1.5 m; the light emitting direction of the wall lamp (D) is backward (back) and forward (front) irradiation, and the vertical distance between the installation position and the ground is 0-2.5 m; full spectrum or far-red spectrum, by intensity adjustment, the local ambient light intensity is not lower than 4000lx, and the maintenance time is not lower than 6h/12h (day).
The applicable conditions are as follows: the general population needs myopia prevention and control; maintaining the hyperopia reserve of the infant; and (3) living illumination in the pseudomyopia remission stage.
The uncomfortable people are: patients suffering from photosensitive skin diseases, cancers or skin diseases who have undergone photodynamic therapy (PDT), etc.
Note that: the excessively high illumination value and the excessively long illumination time at night are avoided, so that the interference of daily work and rest is avoided; the spatial position of the (light-emitting) lamp is kept to avoid uneven distribution of light rays indoors.
3.2 "Emergency repair protocol (S)"
The lamp combination mode is as follows: electric torch (B) or electric torch (B) + desk lamp (A)
Explanation: the flashlight and the desk lamp are internally provided with a strong (650nm far infrared) treatment mode, the flashlight and the desk lamp receive point light source concentrated short-term irradiation through the detachable eye dressing seat, the refractive degree and the length of an eye axis can be controlled and reversed in a short period, and experiments show that the myopia degree can be effectively reversed (the reduction degree per hour is 0.21 to 0.18).
The use method comprises the following steps: the flashlight (B) or the desk lamp (A) is turned to the strong treatment mode, intermittent (three times a day) continuous (three minutes each time) non-direct contact irradiation is carried out, the shortest distance to eyes is 0.5-3cm, one round is formed by three times a day and ten minutes, so that the accumulated light intensity of one round is not lower than 15000lx, and the maintaining time is not lower than 3 rounds per week.
The applicable conditions are as follows: the excessive use of electronic products can cause obvious visual deterioration in a short time, and teenagers can have pseudomyopia at the early and middle stages.
The uncomfortable people are: after eye surgery, patients suffering from acute ocular diseases such as glaucoma, photosensitive skin diseases, cancers or skin diseases subjected to photodynamic therapy (PDT), and mental diseases such as claustrophobia.
Note that: the subjective feeling is closely noticed, and if symptoms such as fever, pain and the like exist, the treatment needs to be stopped in time; the lamp is not directly accessible.
3.3 "common Ocular treatment protocol (G)"
The lamp combination mode is as follows: desk lamp (A) or desk lamp (A) + wall lamp (D) or desk lamp (A) + ceiling lamp (C) or desk lamp (A) + wall lamp (D) + ceiling lamp (C)
Explanation: the full spectrum and/or far-red light is used as a working background light source, so that the intraocular nutrition under normal-intensity working can be supplemented, the tension degree of the intraocular ciliary muscle under the fatigue state is controlled, the sclera anoxia state is relieved, and the experiment shows that the development speed of the myopia degree can be slowed down (1.57-2.16 times).
The use method comprises the following steps: the desk lamp (A) is adjusted to a working mode, or background illumination, namely a wall lamp (D) and a ceiling lamp (C), is added in an auxiliary mode, the total environmental intensity is not lower than 800lx, the distance between the desk lamp and eyes is larger than 0.1m, the single use time is not more than 4h, or the total treatment time is not more than 6h when the desk lamp is used intermittently.
The applicable conditions are as follows: the general population needs myopia prevention and control; eye protection under working and learning conditions; working illumination during pseudomyopia remission.
The uncomfortable people are: patients suffering from photosensitive skin diseases, cancers or skin diseases who have undergone photodynamic therapy (PDT), etc.
Note that: the desk lamp (A) is adjusted to maintain the strength not lower than 800lx (working mode) if the desk lamp (A) is used for a long time (more than 4 h).
3.4 "high intensity Ocular treatment protocol (H)"
The lamp combination mode is as follows: desk lamp (A) + flashlight (B) or desk lamp (A) + flashlight (B) + wall lamp (D) or desk lamp (A) + flashlight (B) + ceiling lamp (C) or desk lamp (A) + flashlight (B) + wall lamp (D) + ceiling lamp (C)
Explanation: when the high-intensity eye-use or long-time use of electronic products for work and study needs higher-intensity background light conditions and intermittent concentrated high-intensity phototherapy, visual fatigue can be effectively relieved, secretion of dopamine in eyes is stimulated, growth of the axes of the eyes is inhibited by adopting a mode of the background light and a handheld mobile therapeutic instrument, and experiments show that myopia degrees can be effectively reversed (degree reduction per hour: left: 0.063 right: 0.612).
The use method comprises the following steps: the desk lamp (A) is adjusted to a working mode, (or) background illumination, namely a wall lamp (D) + a ceiling lamp (C), is added in an auxiliary mode, the total environmental intensity is not lower than 800lx, the distance between the desk lamp and eyes is more than 0.1m, the desk lamp (A) (a strong treatment mode) needs to be used for treatment every 2 hours of working under the environment, the non-direct contact type irradiation lasts for at least three minutes, and the shortest distance is 0.5-3cm from the eyes.
The applicable conditions are as follows: the high-strength electronic screen is suitable for the working and learning population in front of the high-strength electronic screen, the population who has obvious discomfort and visual deterioration when watching the electronic equipment for a long time, and the student population of each age group.
The uncomfortable people are: after eye surgery, patients suffering from acute ocular diseases such as glaucoma, photosensitive skin diseases, cancers or skin diseases subjected to photodynamic therapy (PDT), and mental diseases such as claustrophobia.
Note that: the subjective feeling is closely noticed, and if symptoms such as fever, pain and the like exist, the treatment needs to be stopped in time; the lamp is not directly accessible.
It will be apparent to those skilled in the art that various changes and modifications may be made in the present invention without departing from the spirit and scope of the invention. Thus, if such modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include such modifications and variations.
Claims (1)
1. A method of using a lamp set for treating myopia, using a desk lamp, flashlight, overhead light and wall lamp, the method comprising:
s1 environmental light repair
The lamp combination mode is as follows: a wall lamp is added to the ceiling lamp; or a ceiling light; or a wall lamp;
the use method comprises the following steps: through space planning, the light emitting direction of the suspended ceiling lamp is upward and downward irradiation, and the vertical distance from the mounting position to the top surface is 0.5-1.5 m; the light emitting direction of the wall lamp is backward and forward irradiation, and the vertical distance between the installation position and the ground is 0-2.5 m; the full spectrum or far-red spectrum is adjusted in intensity, so that the light intensity of a local environment is more than or equal to 4000lx, and the maintaining time is more than or equal to 6h or 12 h;
s2, emergency repair
The lamp combination mode is as follows: a flashlight; or a flashlight with a desk lamp;
the use method comprises the following steps: turning the flashlight or the desk lamp to a strong treatment mode, intermittently and continuously irradiating the eye in a non-direct contact manner, wherein the shortest distance is 0.5-3cm, and ten minutes is one round for three times every day, so that the accumulated light intensity of one round is more than or equal to 15000lx, and the maintaining time is more than or equal to 3 rounds per week;
s3 common eye treatment
The lamp combination mode is as follows: a desk lamp; or a desk lamp and a wall lamp; or a desk lamp and a ceiling lamp are added; or a desk lamp, a wall lamp and a ceiling lamp;
the use method comprises the following steps: the desk lamp is adjusted to a working mode, or background illumination is added in an auxiliary mode, namely a wall lamp and a ceiling lamp, the total environment intensity is larger than or equal to 800lx, the distance between the desk lamp and the eyes is larger than 0.1m, the single use time is smaller than or equal to 4h, or the total treatment time is smaller than or equal to 6h when the desk lamp is used intermittently;
s4 high-intensity eye treatment
A lamp combination mode; the desk lamp is provided with a flashlight; or a desk lamp and a flashlight and a wall lamp; or a desk lamp, a flashlight and a ceiling lamp; or a desk lamp, a flashlight, a wall lamp and a ceiling lamp;
the use method comprises the following steps: the desk lamp is adjusted to a working mode, or background illumination is added in an auxiliary mode, namely a wall lamp and a ceiling lamp, the total environment intensity is larger than or equal to 800lx, the distance between the desk lamp and the eyes is larger than 0.1m, the desk lamp is used for treatment every 2 hours in the environment, the non-direct contact type irradiation lasts for more than or equal to three minutes, and the shortest distance between the desk lamp and the eyes is 0.5-3 cm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110283267.6A CN113041505A (en) | 2021-03-17 | 2021-03-17 | Using method of lamp group for treating myopia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110283267.6A CN113041505A (en) | 2021-03-17 | 2021-03-17 | Using method of lamp group for treating myopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113041505A true CN113041505A (en) | 2021-06-29 |
Family
ID=76512904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110283267.6A Pending CN113041505A (en) | 2021-03-17 | 2021-03-17 | Using method of lamp group for treating myopia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113041505A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115216295A (en) * | 2022-07-01 | 2022-10-21 | 旭宇光电（深圳）股份有限公司 | Near-infrared luminescent material, preparation method thereof and luminescent device |
-
2021
- 2021-03-17 CN CN202110283267.6A patent/CN113041505A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115216295A (en) * | 2022-07-01 | 2022-10-21 | 旭宇光电（深圳）股份有限公司 | Near-infrared luminescent material, preparation method thereof and luminescent device |
| CN115216295B (en) * | 2022-07-01 | 2024-02-27 | 旭宇光电（深圳）股份有限公司 | Near infrared luminescent material, preparation method thereof and luminescent device |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018241062B2 (en) | Lighting systems for protecting circadian neuroendocrine function | |
| CN106028583B (en) | Light source device and lighting device | |
| CN110753568B (en) | Light source for eyeball treatment and eyeball treatment device comprising same | |
| WO2021035782A1 (en) | Special light source and light fixture suitable for diabetic retinopathy | |
| CN110085728A (en) | Realize the method and LED light source of low blue light harm, high circadian rhythm factor light | |
| WO2020248748A1 (en) | Led light source for rhythm lighting | |
| CN108245783A (en) | A kind of illumination apparatus for adjusting human boby biorhythm | |
| CN113041505A (en) | Using method of lamp group for treating myopia | |
| CN104848093B (en) | Backlight module with blue light damage improvement design and display module using same | |
| CN101732804B (en) | Circadian rhythm disorder therapeutic instrument and method for manufacturing same | |
| JP2021515959A (en) | Control of human myopia | |
| CN109856860A (en) | A kind of liquid crystal display die set and display device | |
| CN103394165B (en) | The artificial lighting health-care physical therapy instrument of a kind of energy vitamin D and calcium | |
| CN112420902A (en) | Light source module and lighting device comprising same | |
| CN205094776U (en) | A wearable LED eye -shade for improving sleep | |
| CN1287603A (en) | Radiant energy irradiation device | |
| CN214840448U (en) | Light source device for preventing and controlling myopia | |
| CN202488804U (en) | Eye-care table lamp adopting LED (light-emitting diode) light source | |
| CN206207281U (en) | One kind is without blue light without stroboscopic eye protection lamp | |
| CN206577255U (en) | A kind of Phototherapeutic device | |
| AU2021101739A4 (en) | Dedicated Light Source and Lamp for Diabetic Retinopathy | |
| CN216394458U (en) | Medical isolation eye patch for relieving anxiety | |
| CN218468988U (en) | Optical lens and double-sided optical prism combined structure on LED linear lamp | |
| CN215385123U (en) | Eye protection instrument | |
| WO2023125740A1 (en) | Lighting devices, lighting systems, methods and components |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210629 |
|
| RJ01 | Rejection of invention patent application after publication |